Ozette, a Seattle, WA-based creator of an artificial intelligence-powered immune monitoring platform, raised $6m in seed financing.
The round was led by Madrona Venture Group, with participation from Allen Institute for Artificial Intelligence (AI2) and Vulcan Capital.
The company, a collaboration between the Fred Hutchinson Cancer Research Center and AI2, will use the seed funding to accelerate innovation in treating disease.
Co-founded by Raphael Gottardo and Chief Technology Officer Greg Finak, who are recognized leaders in single-cell analysis, and led by Dr. Ali Ansary, CEO, Ozette provides an Immune Monitoring Platform that enables scientists to quickly extract reliable insights from single-cell data across instruments, experiments and disease states. Having this fully annotated data allows interpretable results for decision-making that will improve patient care and patient outcomes.